title: [Immunogenetic predictors of a rapid virologic response to antiviral therapy in patients with chronic hepatitis C].
abstract: OBJECTIVE
  To determine the correlation between interleukin 28B (IL28B) gene polymorphism in patients with chronic hepatitis C (CHC), the presence or absence a rapid virologic response to antiviral therapy, and a number of immunological characteristics as a basis for a personalized approach to treating the patients.
  
  
  METHODS
  Seventeen CHC patients infected with hepatitis C virus genotype 1b were examined and underwent genetic testing for IL28B gene polymorphism for rs12979860 (CC, CT or TT genotypes) and rs8099917 (TT, TG or GG genotypes) using the modified method of adjacent samples, which revealed single nucleotide substitutions in the genes. Their immunological parameters were identified by a flow cytometry technique by taking into account whether a rapid virologic response had been achieved.
  
  
  RESULTS
  The key phenomena of a rapid virologic response in the representatives of different IL28B genotypes are the nonspecific proliferative activity of blood natural killer cells before treatment, as well as the count of regulatory T cells before and 4 weeks after therapy start.
  
  
  CONCLUSIONS
  To predict the efficiency of antiviral therapy for CHC, it is desirable to supplement genetic studies with immunological data.
authors.forename: N D
authors.initials: ND
authors.lastname: Yushchuk
authors.forename: O O
authors.initials: OO
authors.lastname: Znoiko
authors.forename: I P
authors.initials: IP
authors.lastname: Balmasova
authors.forename: N V
authors.initials: NV
authors.lastname: Fedoseyeva
authors.forename: E V
authors.initials: EV
authors.lastname: Shmeleva
authors.forename: K R
authors.initials: KR
authors.lastname: Dudina
authors.forename: E A
authors.initials: EA
authors.lastname: Klimova
authors.forename: T V
authors.initials: TV
authors.lastname: Petrova
authors.forename: D Yu
authors.initials: DY
authors.lastname: Trofimov
authors.forename: P A
authors.initials: PA
authors.lastname: Belyi
authors.forename: N Kh
authors.initials: NKh
authors.lastname: Safiullina
authors.forename: E V
authors.initials: EV
authors.lastname: Pypkina
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005434:Flow Cytometry; D005820:Genetic Testing; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D006801:Humans; D055261:Immunogenetic Phenomena; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda